GPR-CM05P-100μg / 询价
GPR-CM05P-100μg x 5 / 询价
GPR-CM05P-100μg x 10 / 询价
- 客服电话
- 技术支持
Cynomolgus GPRC5D Protein-VLP
Recombinant Cynomolgus GPRC5D Protein-VLP is expressed from HEK293. It contains Met1-Cys300 [Accession | A0A2K5W6I7].
The target protein has a predicted MW of 35.10 kDa.
>95% as determined by HPLC
Less than 1 EU per μg by the LAL method.
Supplied as 0.22 μm filtered solution in PBS, 300 mM L-Arginine (pH 7.4). Notice: If you need it for immunization, water-soluble adjuvant is recommended.
Valid for 12 months from date of receipt when stored at -80°C.; Recommend to aliquot the protein into smaller quantities for optimal storage. Please minimize freeze-thaw cycles.
The purity of Cynomolgus GPRC5D VLP is greater than 95% as determined by SEC-HPLC.
Immobilized Cynomolgus GPRC5D VLP (100 μl/well) at 5 μg/ml (100 μl/Well) on the plate. Dose response curve for Anti-GPRC5D Antibody, hFc Tag with the EC50 of 6.91 μg/ml determined by ELISA.
Chimeric antigen receptor (CAR) T cells, a type of cell-based immunotherapy, have shown some promising results in multiple myeloma, a bone marrow cancer. The orphan G protein–coupled receptor, class C group 5 member D (GPRC5D), normally expressed only in the hair follicle, Using quantitative immunofluorescence, we determined that GPRC5D protein is expressed on CD138 MM cells from primary marrow samples with a distribution that was similar to, but independent of, BCMA.
GPRC5D; MGC129713; MGC129714; orphan G-protein coupled receptor
(1) Smith EL, Harrington K, Staehr M, Masakayan R, Jones J, Long TJ, Ng KY, Ghoddusi M, Purdon TJ, Wang X, Do T, Pham MT, Brown JM, De Larrea CF, Olson E, Peguero E, Wang P, Liu H, Xu Y, Garrett-Thomson SC, Almo SC, Wendel HG, Riviere I, Liu C, Sather B, Brentjens RJ. GPRC5D is a target for the immunotherapy of multiple myeloma with rationally designed CAR T cells. Sci Transl Med. 2019 Mar 27;11(485):eaau7746. doi: 10.1126/scitranslmed.aau7746. PMID: 30918115; PMCID: PMC7508042.
